The state of Arizona currently has 17 active clinical trials seeking participants for Migraine research studies. These trials are conducted in various cities, including Phoenix, Tucson, Scottsdale and Mesa.
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
05/22/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +2 locations
Conditions: Migraine
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
Recruiting
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/22/2025
Locations: Wake Research/ Tucson Neuroscience Research, Tucson, Arizona
Conditions: Acute Migraine
A PIVOTAL STUDY EVALUATING SAFETY and EFFICACY of the SHIRATRONICS MIGRAINE THERAPY SYSTEM
Recruiting
Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/04/2025
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: Headache Migraine Chronic
Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine
Recruiting
The goal of this study is to compare the efficacy and adverse events of inhaled isopropyl alcohol vapor (IAV) versus placebo (inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) for treating nausea associated with acute migraine attacks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/27/2025
Locations: HonorHealth Bob Bové Neuroscience Institute, Scottsdale, Arizona
Conditions: Migraine
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
Recruiting
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2024
Locations: Mayo Clinic in Arizona, Phoenix, Arizona
Conditions: Migraine